Simulations Plus, Inc.
SLPSimulations Plus, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +43.4% in a year while annual EPS moved −757.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages. Underneath, the last four quarters read mixed, and 167% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Simulations Plus, Inc. trades at $18.4, between stages. That is +13.3% against its own 200-day average. It sits at 74% of a 52-week range of $11 to $21. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 14 straight weeks.
Today the stock is between stages. At $18.4 it trades +13.3% versus its 200-day average and sits at 74% of its 52-week range ($11–$21).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +8% while the S&P 500 moved +24% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Simulations Plus, Inc. trades at 46.0× P/E, against too little history to rank. Its long-run median P/E is 40.7×, measured across 0.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 46.0× is against too little history to rank, against a long-run median of 40.7× measured over 0.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −757.1% against a +43.4% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Simulations Plus, Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 0.0% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.3% | +17.0% | — | — |
| Stock price | +43.4% | — | — | — |
4-Factor Sector Score
64.2/100 — rank 2 of 29 in Health Information Services · 52% evidence confidence
Simulations Plus, Inc. scores 64.2 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 24.6 + 16.2 + 10.3 + 13.1 = 64.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Simulations Plus, Inc. reported $0.0 B of revenue in the Feb 26 quarter, +0.0% year on year. Over 4 years it has compounded at 12.5% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.1 B.
FY25 revenue came in at $0.1 B (+14.3% on the year), capping 4 years at 12.5% compound. The latest quarter (Feb 26) printed $0.0 B, +0.0% year on year.
Pace check: the last four quarters averaged +0.0% growth against the decade's 12.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.0% over the last 4 quarters against +6.9%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Simulations Plus, Inc.'s operating margin is 50.0% in the Feb 26 quarter, +50.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −87.5% to 20.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 50.0%, +50.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −87.5%–20.0%.
Why the margin moved: operating margin went +50.0 pp year on year while gross margin went +50.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Simulations Plus, Inc. earned $0.0 B of net profit in the Feb 26 quarter. The full FY25 year was a loss of $0.1 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.
Feb 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $−0.1 B (−700.0%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 167% of Simulations Plus, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.0 B of operating cash against $−0.1 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash.
FY25: operating cash of $0.0 B against reported profit of $−0.1 B, leaving free cash of $0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 167% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Simulations Plus, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Simulations Plus, Inc. earns a ROE of −50% in FY25. Return on invested capital clears the cost of that capital by −2.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −75.0% net margin on 0.62× asset turns.
FY25 ROE is −50%.
🚨 Why the return is what it is — the wiring (FY25): −75.0% net margin × 0.62× asset turns × 1.08× balance-sheet leverage ≈ −50.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 8.9% − 11.4% = a −2.5 pp spread. The 11.4% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Simulations Plus, Inc. paid $0.24 per share over the last four reported quarters. The most recent declaration was $0.06 for Aug 24. Against the current price of $18.4 that is a trailing yield of 1.31%, measured on dividends already paid rather than on a forecast.
Simulations Plus, Inc. paid $0.24 per share across the last four reported quarters, most recently $0.06 for Aug 24. Against the current price of $18.4 the trailing twelve months work out to 1.31% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Simulations Plus, Inc. carries total debt of $0.0 B against shareholder equity of $0.1 B as of May 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
May 26: total debt of $0.0 B against shareholder equity of $0.1 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
10.6% of Simulations Plus, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 2.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 10.6% of the float is sold short, and at typical trading volumes it would take about 2.6 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Simulations Plus, Inc.: the Z-score reads 14.84. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 14.84 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 14.84.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1HealthEquity, Inc.HQY | 67.9/100Favorable setup85% evidence | BREAKING OUT | 23.6/35 Revenue 7.6% · PAT 89.3% · OPM change 3.9 pp 95% evidence | 15.5/25 ROCE 3.2% · OPM 29% 76% evidence | 12.4/20 P/E 30.7× · PEG 1.57 65% evidence | 16.4/20 RS sector 4.3% · RS bench 5.3% · 1Y 12.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 15.5 + 12.4 + 16.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Simulations Plus, Inc.this pageSLP | 64.2/100Thin evidence · provisional52% evidence | LEADER | 24.6/35 Revenue — · PAT — · OPM change 11.1 pp 45% evidence | 16.2/25 ROCE 3.4% · OPM 23.2% 76% evidence | 10.3/20 P/E 42.8× · PEG — 15% evidence | 13.1/20 RS sector 2.4% · RS bench 3.2% · 1Y 29.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.6 + 16.2 + 10.3 + 13.1 = 64.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Hinge Health, Inc.HNGE | 61.7/100Mixed-positive evidence62% evidence | LEADER | 19.9/35 Revenue 49.5% · PAT -1748.4% · OPM change 7 pp 83% evidence | 15.1/25 ROCE 8.4% · OPM 17.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.7/20 RS sector 35% · RS bench 35.8% · 1Y 40.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 19.9 + 15.1 + 10 + 16.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Veeva Systems Inc.VEEV | 61.5/100Mixed-positive evidence85% evidence | BREAKING OUT | 20.5/35 Revenue 16.3% · PAT 20.5% · OPM change 0.1 pp 95% evidence | 17.7/25 ROCE 4% · OPM 30.9% 76% evidence | 13.8/20 P/E 27.8× · PEG 1.47 65% evidence | 9.5/20 RS sector -12.6% · RS bench -13% · 1Y -24.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 17.7 + 13.8 + 9.5 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 510x Genomics, Inc.TXG | 56.9/100Mixed-positive evidence61% evidence | LEADER | 20.1/35 Revenue 2.2% · PAT — · OPM change 14.1 pp 62% evidence | 6.8/25 ROCE -2% · OPM -11.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 91.7% · RS bench 96.6% · 1Y 289.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 6.8 + 10 + 20 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6BrightSpring Health Services, Inc.BTSG | 56.2/100Thin evidence · provisional58% evidence | LEADER | 19.7/35 Revenue — · PAT — · OPM change 1.6 pp 45% evidence | 12.7/25 ROCE 2.9% · OPM 3.4% 76% evidence | 10.1/20 P/E 44.4× · PEG — 15% evidence | 13.7/20 RS sector 27.5% · RS bench 31.3% · 1Y 202.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 12.7 + 10.1 + 13.7 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7HealthStream, Inc.HSTM | 55.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 19.0/35 Revenue 6.5% · PAT 5.3% · OPM change 3.3 pp 83% evidence | 14.2/25 ROCE 1.9% · OPM 9.3% 76% evidence | 5.6/20 P/E 30.9× · PEG 4.87 65% evidence | 17.0/20 RS sector 8.6% · RS bench 9.2% · 1Y 14.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 14.2 + 5.6 + 17 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Omada Health, Inc.OMDA | 53.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 25.2/35 Revenue 49% · PAT — · OPM change 9.2 pp 62% evidence | 7.0/25 ROCE -2.9% · OPM -6.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.4/20 RS sector 1.2% · RS bench 0.6% · 1Y 6.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 25.2 + 7 + 10 + 11.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Phreesia, Inc.PHR | 49.2/100Mixed-negative evidence67% evidence | BREAKING OUT | 22.7/35 Revenue 13.8% · PAT 100% · OPM change 8 pp 71% evidence | 10.9/25 ROCE 1.7% · OPM 5.2% 76% evidence | 9.7/20 P/E 61.4× · PEG — 15% evidence | 5.9/20 RS sector -34.4% · RS bench -35.7% · 1Y -57.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.7 + 10.9 + 9.7 + 5.9 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Omnicell, Inc.OMCL | 47.3/100Thin evidence · provisional58% evidence | ASLEEP | 21.4/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 12.8/25 ROCE 2.1% · OPM 5.4% 76% evidence | 9.9/20 P/E 49.4× · PEG — 15% evidence | 3.2/20 RS sector -15.2% · RS bench -13.5% · 1Y 20.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 12.8 + 9.9 + 3.2 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11SOPHiA GENETICS SASOPH | 47.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 17.4/35 Revenue 19.1% · PAT — · OPM change 10.5 pp 62% evidence | 3.6/25 ROCE -15.1% · OPM -79.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 26.6% · RS bench 29.3% · 1Y 115.1%6 of 12 weeks ahead 70% evidence |
| Exact sum: 17.4 + 3.6 + 10 + 16 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Weave Communications, Inc.WEAV | 46.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.7/35 Revenue 16.4% · PAT — · OPM change 7.5 pp 62% evidence | 5.6/25 ROCE -5.1% · OPM -9.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.2/20 RS sector -2.5% · RS bench -2.2% · 1Y -9.2%8 of 12 weeks ahead 70% evidence |
| Exact sum: 21.7 + 5.6 + 10 + 9.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Waystar Holding Corp.WAY | 46.1/100Thin evidence · provisional58% evidence | TURNING | 16.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence | 12.6/25 ROCE 1.5% · OPM 25.6% 76% evidence | 11.0/20 P/E 29.3× · PEG — 15% evidence | 5.9/20 RS sector -25.5% · RS bench -25.7% · 1Y -31.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 12.6 + 11 + 5.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14NRC HealthNRC | 45.7/100Thin evidence · provisional52% evidence | FADING | 12.6/35 Revenue — · PAT — · OPM change -9.6 pp 45% evidence | 11.5/25 ROCE -3.1% · OPM 16% 76% evidence | 9.0/20 P/E 86.3× · PEG — 15% evidence | 12.6/20 RS sector 1.5% · RS bench 3.4% · 1Y 29.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 12.6 + 11.5 + 9 + 12.6 = 45.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15TruBridge, Inc.TBRG | 45.3/100Thin evidence · provisional58% evidence | 10.9/35 Revenue 0% · PAT — · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 0.9% · OPM 3.5% 76% evidence | 9.2/20 P/E 73.2× · PEG — 15% evidence | 15.2/20 RS sector 5.2% · RS bench 11% · 1Y 18.9%8 of 8 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 10.9 + 10 + 9.2 + 15.2 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Carlsmed, Inc.CARL | 45.2/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.3/35 Revenue 75% · PAT — · OPM change -1.5 pp 62% evidence | 4.2/25 ROCE -11.7% · OPM -57.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.7/20 RS sector -2.3% · RS bench -1.5% · 1Y 5.6%4 of 12 weeks ahead 70% evidence |
| Exact sum: 21.3 + 4.2 + 10 + 9.7 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Privia Health Group, Inc.PRVA | 44.2/100Mixed-negative evidence81% evidence | ASLEEP | 22.8/35 Revenue 24.7% · PAT 40% · OPM change 0.1 pp 83% evidence | 11.1/25 ROCE 1% · OPM 1.2% 76% evidence | 4.7/20 P/E 128.6× · PEG 3.86 65% evidence | 5.6/20 RS sector -10.3% · RS bench -9.2% · 1Y 15.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 11.1 + 4.7 + 5.6 = 44.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 15.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 18GoodRx Holdings, Inc.GDRX | 42.2/100Mixed-negative evidence65% evidence | BREAKING OUT | 8.6/35 Revenue -1.3% · PAT -31% · OPM change -4.3 pp 83% evidence | 11.0/25 ROCE 1.2% · OPM 7.2% 76% evidence | 10.4/20 P/E 32.7× · PEG — 15% evidence | 12.2/20 RS sector 1.7% · RS bench 1% · 1Y -3.7%11 of 12 weeks ahead 70% evidence |
| Exact sum: 8.6 + 11 + 10.4 + 12.2 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Doximity, Inc.DOCS | 40.7/100Mixed-negative evidence81% evidence | ASLEEP | 11.6/35 Revenue 13% · PAT -11.7% · OPM change -18.1 pp 83% evidence | 15.9/25 ROCE 2.4% · OPM 17.1% 76% evidence | 11.3/20 P/E 23.8× · PEG 1.84 65% evidence | 1.9/20 RS sector -49.3% · RS bench -50.6% · 1Y -67.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 15.9 + 11.3 + 1.9 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Talkspace, Inc.TALK | 40.6/100Mixed-negative evidence64% evidence | ASLEEP | 12.9/35 Revenue 22.7% · PAT -66.7% · OPM change -9.5 pp 62% evidence | 6.0/25 ROCE -6.2% · OPM -11.6% 76% evidence | 8.5/20 P/E 517.5× · PEG — 15% evidence | 13.2/20 RS sector 8.3% · RS bench 12% · 1Y 106%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 6 + 8.5 + 13.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21HeartFlow, Inc.HTFL | 39.7/100Thin evidence · provisional55% evidence | ASLEEP | 20.1/35 Revenue 40.4% · PAT — · OPM change -9.1 pp 62% evidence | 4.0/25 ROCE -13.2% · OPM -56.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -18% · RS bench -17.4% · 1Y -12.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.1 + 4 + 10 + 5.6 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Schrödinger, Inc.SDGR | 37.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.8/35 Revenue 10.9% · PAT — · OPM change 2.2 pp 62% evidence | 4.9/25 ROCE -9.4% · OPM -83.3% 76% evidence | 9.6/20 P/E 66.3× · PEG — 15% evidence | 7.2/20 RS sector -11.9% · RS bench -12.2% · 1Y -18.5%10 of 12 weeks ahead 70% evidence |
| Exact sum: 15.8 + 4.9 + 9.6 + 7.2 = 37.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Tempus AI, Inc.TEM | 37.1/100Thin evidence · provisional55% evidence | ASLEEP | 19.0/35 Revenue — · PAT — · OPM change 2.6 pp 45% evidence | 5.4/25 ROCE -4.8% · OPM -24.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.7/20 RS sector -32.9% · RS bench -33.2% · 1Y -22.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 5.4 + 10 + 2.7 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Spok Holdings, Inc.SPOK | 36.0/100Mixed-negative evidence75% evidence | BASING | 8.4/35 Revenue -1.4% · PAT -18.8% · OPM change -9.2 pp 83% evidence | 13.0/25 ROCE 1.6% · OPM 7.4% 76% evidence | 9.7/20 P/E 18.2× · PEG 2.25 65% evidence | 4.9/20 RS sector -23.7% · RS bench -23.5% · 1Y -38.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 8.4 + 13 + 9.7 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Claritev CorporationCTEV | 36.0/100Thin evidence · provisional55% evidence | ASLEEP | 13.1/35 Revenue 5.8% · PAT — · OPM change -3.1 pp 62% evidence | 8.9/25 ROCE 0.1% · OPM 2.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.0/20 RS sector -33.5% · RS bench -35.5% · 1Y -53.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 13.1 + 8.9 + 10 + 4 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Certara, Inc.CERT | 35.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 12.0/35 Revenue 6.8% · PAT — · OPM change -11.2 pp 62% evidence | 8.8/25 ROCE -0.3% · OPM -4% 76% evidence | 8.7/20 P/E 174.6× · PEG — 15% evidence | 6.1/20 RS sector -14.8% · RS bench -15.5% · 1Y -28.7%6 of 12 weeks ahead 70% evidence |
| Exact sum: 12 + 8.8 + 8.7 + 6.1 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Evolent Health, Inc.EVH | 32.7/100Thin evidence · provisional55% evidence | ASLEEP | 11.3/35 Revenue -21.3% · PAT — · OPM change -1.8 pp 62% evidence | 8.1/25 ROCE -0.6% · OPM -2.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.3/20 RS sector -42.2% · RS bench -43.6% · 1Y -65.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 11.3 + 8.1 + 10 + 3.3 = 32.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28LifeMD, Inc.LFMD | 31.0/100Thin evidence · provisional58% evidence | ASLEEP | 12.3/35 Revenue 36.9% · PAT — · OPM change -15.5 pp 62% evidence | 4.0/25 ROCE -53.7% · OPM -17.8% 76% evidence | 9.4/20 P/E 72.2× · PEG — 15% evidence | 5.3/20 RS sector -21.5% · RS bench -21.8% · 1Y -42.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4 + 9.4 + 5.3 = 31 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Teladoc Health, Inc.TDOC | 41.9/100Thin evidence · provisional49% evidence | ASLEEP | 18.6/35 Revenue — · PAT — · OPM change 9.1 pp 45% evidence | 6.8/25 ROCE -1.9% · OPM -10.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.5/20 RS sector -14.6% · RS bench -14.6% · 1Y -3.6%10 of 12 weeks ahead 70% evidence |
| Exact sum: 18.6 + 6.8 + 10 + 6.5 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Simulations Plus, Inc.'s stock price today?
Simulations Plus, Inc. trades at $18.4, +43.4% over the past year. The company is valued at $0.0 B. The stock sits at 74% of its 52-week range of $11–$21, +13.3% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 14 weeks. — as of 5 August 2026.
What were Simulations Plus, Inc.'s latest quarterly results?
Simulations Plus, Inc. reported revenue of $0.0 B and net profit of $0.0 B for the Feb 26 quarter. Earnings per share were $0.22. The operating margin was 50.0%, 50.0 pp higher than a year earlier. — as of 5 August 2026.
What is Simulations Plus, Inc.'s revenue?
Simulations Plus, Inc. reported revenue of $0.0 B in the Feb 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.1 B (+14.3%). Over the last 4 years revenue compounded at 12.5% a year. — as of 5 August 2026.
What is Simulations Plus, Inc.'s profit?
Simulations Plus, Inc. earned $0.0 B of net profit in the Feb 26 quarter. Full-year FY25 profit was $−0.1 B. The operating margin ran 50.0% in the latest quarter. — as of 5 August 2026.
What is Simulations Plus, Inc.'s market cap?
Simulations Plus, Inc.'s market capitalisation is $0.0 B at a stock price of $18.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Simulations Plus, Inc. pay a dividend?
Yes — Simulations Plus, Inc. declared $0.06 per share for Aug 24, and $0.24 per share across the last four reported quarters. — as of 5 August 2026.
What is Simulations Plus, Inc.'s dividend per share?
Simulations Plus, Inc.'s most recently declared dividend is $0.06 per share for Aug 24, giving $0.24 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Simulations Plus, Inc.'s dividend yield?
Simulations Plus, Inc.'s trailing dividend yield is 1.31%: $0.24 declared per share across the last four reported quarters, against a share price of $18.4. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
How is Simulations Plus, Inc. performing?
Simulations Plus, Inc.'s latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Simulations Plus, Inc. in?
Mixed — no clean majority across the growth curves, ROCE holding at 0.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +0.0% latest, eps growth −994.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Simulations Plus, Inc. beating the market?
On recent form, yes — Simulations Plus, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 14 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +8% against the S&P 500's +24% — behind the index over the full window. — as of 5 August 2026.
Will Simulations Plus, Inc.'s stock price go up?
This page publishes no price forecast for Simulations Plus, Inc. What it measures instead: the stock price is $18.4. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Simulations Plus, Inc.?
Yes — short interest is 10.6% of Simulations Plus, Inc.'s tradable float, about 2.6 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is Simulations Plus, Inc.'s capex?
Simulations Plus, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Simulations Plus, Inc.'s cash flow?
Simulations Plus, Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Simulations Plus, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 167% of Simulations Plus, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.0 B against reported profit of $−0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Simulations Plus, Inc.?
On the balance sheet, the Z-score reads 14.84 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Simulations Plus, Inc. in its business cycle?
Simulations Plus, Inc.'s FY25 operating margin was −87.5%, against a 5-year band of −87.5%–20.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 50.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Simulations Plus, Inc. story?
The sharpest disagreement: the price moved +43.4% in a year while annual EPS moved −757.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Simulations Plus, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Simulations Plus, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.